National survey findings on law enforcement agency drug response practices, overdose victim outcomes, and Good Samaritan Laws.

Richardson NJ, Ray B, Smiley-McDonald HM, Davis CS, Kral AH

The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018.

Howlader N, Sharon E, Bhattacharya M, Ehrlich LA, Richardson NC, Gormley NJ, de Claro RA, Wood AE, Mariotto AB, Cronin KA

Regulation of metabolic health by dietary histidine in mice.

Flores V, Spicer AB, Sonsalla MM, Richardson NE, Yu D, Sheridan GE, Trautman ME, Babygirija R, Cheng EP, Rojas JM, Yang SE, Wakai MH, Hubbell R, Kasza I, Tomasiewicz JL, Green CL, Dantoin C, Alexander CM, Baur JA, Malecki KC, Lamming DW

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk, RECOVERY Collaborative Group

Fluid Optimisation in Emergency Laparotomy (FLO-ELA) Trial: study protocol for a multi-centre randomised trial of cardiac output-guided fluid therapy compared to usual care in patients undergoing major emergency gastrointestinal surgery.

Edwards MR, Forbes G, Walker N, Morton DG, Mythen MG, Murray D, Anderson I, Mihaylova B, Thomson A, Taylor M, Hollyman M, Phillips R, Young K, Kahan BC, Pearse RM, Grocott MPW, FLO-ELA investigators

Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023.

Kissling E, Maurel M, Emborg HD, Whitaker H, McMenamin J, Howard J, Trebbien R, Watson C, Findlay B, Pozo F, Bolt Botnen A, Harvey C, Rose A, European IVE group, Members of the European IVE group

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.

Pairo-Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, Nassiri I, McConkey GA, Zechner M, Klaric L, Griffiths F, Oosthuyzen W, Kousathanas A, Richmond A, Millar J, Russell CD, Malinauskas T, Thwaites R, Morrice K, Keating S, Maslove D, Nichol A, Semple MG, Knight J, Shankar-Hari M, Summers C, Hinds C, Horby P, Ling L, McAuley D, Montgomery H, Openshaw PJM, Begg C, Walsh T, Tenesa A, Flores C, Riancho JA, Rojas-Martinez A, Lapunzina P, GenOMICC Investigators, SCOURGE Consortium, ISARICC Investigators, 23andMe COVID-19 Team, Yang J, Ponting CP, Wilson JF, Vitart V, Abedalthagafi M, Luchessi AD, Parra EJ, Cruz R, Carracedo A, Fawkes A, Murphy L, Rowan K, Pereira AC, Law A, Fairfax B, Hendry SC, Baillie JK

The statistical fragility of the distal fibula fracture literature: A systematic review of randomized controlled trials.

Mian H, Megafu M, Megafu E, Singhal S, Richardson NG, Tornetta P 3rd, Parisien RL

The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.

Goldswain H, Dong X, Penrice-Randal R, Alruwaili M, Shawli GT, Prince T, Williamson MK, Raghwani J, Randle N, Jones B, Donovan-Banfield I, Salguero FJ, Tree JA, Hall Y, Hartley C, Erdmann M, Bazire J, Jearanaiwitayakul T, Semple MG, Openshaw PJM, Baillie JK, ISARIC4C Investigators, Emmett SR, Digard P, Matthews DA, Turtle L, Darby AC, Davidson AD, Carroll MW, Hiscox JA

A national survey of law enforcement post-overdose response efforts.

Ray B, Richardson NJ, Attaway PR, Smiley-McDonald HM, Davidson P, Kral AH

Post-overdose follow-up in the community with peer recovery specialists: The Lake Superior Diversion and Substance Use Response Team.

Ray B, McCarthy-Nickila J, Richardson N, Maahs J

A high-mass X-ray binary descended from an ultra-stripped supernova.

Richardson ND, Pavao CM, Eldridge JJ, Pablo H, ChenĂŠ AN, Wysocki P, Gies DR, Younes G, Hare J

Understanding shedders: Which socio-demographic, health and wellbeing characteristics best inform appropriate health promotion action in men's sheds and a 'Shed for Life'?

McGrath A, Murphy N, Egan T, Ormond G, Richardson N

Supporting farmer wellbeing: exploring a potential role for farm advisory staff.

Hammersley C, Richardson N, Meredith D, Carroll P, McNamara J

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.

Liew F, Talwar S, Cross A, Willett BJ, Scott S, Logan N, Siggins MK, Swieboda D, Sidhu JK, Efstathiou C, Moore SC, Davis C, Mohamed N, Nunag J, King C, Thompson AAR, Rowland-Jones SL, Docherty AB, Chalmers JD, Ho LP, Horsley A, Raman B, Poinasamy K, Marks M, Kon OM, Howard L, Wootton DG, Dunachie S, Quint JK, Evans RA, Wain LV, Fontanella S, de Silva TI, Ho A, Harrison E, Baillie JK, Semple MG, Brightling C, Thwaites RS, Turtle L, Openshaw PJM, ISARIC4C Investigators, PHOSP-COVID collaborative group